Sažetak
Aim: We aimed to examine how oxidative stress changes after treatment and its relationship with metabolic parameters in patients diagnosed with Type 2 Diabetes Mellitus and given metformin or metformin-pioglitazone combination.
Methods: The study population consisted of a total of 60 patients, including the group diagnosed with Type 2 Diabetes Mellitus (T2DM) and given metformin 2x1000 mg (n=30) and the group given metformin-pioglitazone 2x15/1000 mg combination (n=30). Serum IMA (ischemia modified albumin), TAS (total antioxidant status), TOS (total oxidant status) and thiol - disulphide homeostasis were measured before and after 12 weeks of treatment.
Results: No significant change was detected in Native SH and Total SH levels in both Metformin and combination groups. IMA level increased significantly in both drug groups (p=0.03, p=0.01, respectively). Although the TAS level increased in both groups, no significant change was detected. While TOS and OSI index decreased significantly in the combination group (p<0.001), the decrease was not significant in the metformin group. No significant difference was detected between Native SH, Total SH, Disulfide, IMA, TAS, TOS levels and OSI index changes of both drug groups.
Conclusion: We found that the anti-diabetic drugs used did not have a significant effect on oxidative stress.
Ključne reči
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.